pravastatin has been researched along with Arteriosclerosis in 113 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 56 (49.56) | 18.2507 |
| 2000's | 56 (49.56) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (0.88) | 2.80 |
| Authors | Studies |
|---|---|
| Buckett, L; Davidson, R; Holdgate, G; McCormick, A; McTaggart, F; Schneck, D; Smith, G; Warwick, M | 1 |
| Bu, X; Li, C; Liu, Y | 1 |
| Libby, P; Sukhova, GK; Williams, JK | 1 |
| Shah, PK | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ; Vernalis, MN | 1 |
| Anderson, JL; Zebrack, JS | 1 |
| Aronov, DM; Bubnova, MG | 1 |
| Arnesen, H; Eid, HM; Eritsland, J; Larsen, J; Seljeflot, I | 1 |
| Belenkov, YN; Kaminnyi, AI; Konovalova, GG; Kukharchuk, VV; Lankin, VZ; Pisarenko, OI; Shumaev, KB; Tikhaze, AK | 1 |
| Burger, F; Graber, P; Kwak, BR; Lüscher, TF; Mach, F; Matter, CM; Mulhaupt, F; Pelli, G; Veillard, NR | 1 |
| Domínguez, J; Schultz, M | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Egashira, K; Hirouchi, Y; Inoue, S; Kitajima, S; Kitamoto, S; Kohjimoto, Y; Nakano, K; Usui, M | 1 |
| Bell, PR; Loftus, IM; Molloy, KJ; Naylor, AR; Schwalbe, EC; Thompson, MM | 1 |
| Buchholz, K; Fliser, D; Haller, H | 1 |
| Hayashi, M; Ichihara, A; Kaneshiro, Y; Koura, Y; Saruta, T; Tada, Y | 1 |
| Gordon, BR; Levine, DM; Parker, TS; Rosenson, RS; Tangney, CC | 1 |
| Chudleigh, R; Platts, J | 1 |
| Kurachi, O; Maruo, T; Matsuo, H; Nakago, S; Oki, N; Takeuchi, K; Yamanaka, Y | 1 |
| Adams, GJ; Ballantyne, CM; Greene, J; Harrist, R; Insull, W; Karmonik, C; Kimball, KT; Morrisett, JD; Vick, GW | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Angelini, G; Carson, K; George, S; Jackson, C; Johnson, J; Karanam, S; Newby, A; Williams, H | 1 |
| Benderitter, M; Gaugler, MH; Squiban, C; Vandamme, M; Vereycken-Holler, V; Vozenin-Brotons, MC | 1 |
| Almeida, EA; Carneiro, A; Jorge, M; Jorge, PA; Ozaki, MR | 1 |
| Bermas, B; Costenbader, KH; de Pablo, P; Finckh, A; Gall, V; Karlson, EW; Liang, MH; Lynch, M; Schur, PH | 1 |
| Nyssönen, K; Porkkala-Sarataho, E; Salonen, JT; Salonen, R | 1 |
| Bond, MG; Byington, RP; Crouse, JR; Espeland, MA; Furberg, CD | 1 |
| Byington, RP; Furberg, CD; McGovern, ME; Park, JS; Pitt, B | 1 |
| Fukami, M; Fukushige, J; Hosokawa, T; Ito, T; Shiomi, M; Tamura, A; Tsujita, Y; Tsukada, T; Watanabe, Y; Yata, T | 1 |
| Bruschke, AV; Byington, RP; Furberg, CD; Hoen, H; Jukema, JW; Mancini, GB; Pitt, B; Salonen, JT | 1 |
| Bernini, F; Corsini, A; Fumagalli, R; Paoletti, R; Raiteri, M; Soma, MR | 1 |
| Braun, P; May, E; Merz, M; Park, JW; Vermeltfoort, M | 1 |
| Belder, R; Nyyssönen, K; Park, JS; Porkkala, E; Rummukainen, J; Salonen, JT; Salonen, R | 1 |
| Bond, MG; Byington, RP; Craven, TE; Crouse, JR; Espeland, MA; Furberg, CD; McGovern, ME; Sprinkle, JW | 1 |
| Tsujita, Y | 1 |
| Notkola, IL; Rouhiainen, H; Rouhiainen, P; Salonen, JT | 1 |
| Buikema, H; de Wilde, PC; Demacker, PN; Kroon, AA; Leijten, PA; Stalenhoef, AF; van Gilst, WH | 1 |
| Arnaboldi, L; Corsini, A; Fumagalli, R; Paoletti, R; Quarato, P; Raiteri, M | 1 |
| Cooper, ME; Gilbert, RE; Jerums, G | 1 |
| Rouhiainen, H; Rouhiainen, P; Salonen, JT | 2 |
| Davis, BR; Meyers, DG; Rouleau, JL; Sacks, FM; Wilt, TJ | 1 |
| Aoyagi, S; Matsuzaki, M; Morikuni, C; Okada, K; Okuda, F; Ono, S; Tanaka, N; Tokisawa, I; Tomochika, Y; Wasaki, Y | 1 |
| Ashraf, T; Crouse, J; Davidson, M; Furberg, CD; Hay, JW; Pitt, B; Radican, L; Wittels, E | 1 |
| Nyyssönen, K; Porkkala-Sarataho, E; Salonen, JT | 1 |
| Clem, JR | 1 |
| Buckley, BM; Murphy, MB; Vaughan, CJ | 1 |
| Braesen, JH; Harsch, M; Niendorf, A | 1 |
| Fager, G; Lennernäs, H | 1 |
| Biwa, T; Hakamata, H; Horiuchi, S; Kobori, S; Matsumura, T; Sakai, M; Sato, Y; Shichiri, M; Takemura, T | 1 |
| Zanchetti, A | 1 |
| Jorge, PA | 1 |
| Herrington, DM; Libby, P; Sukhova, GK; Williams, JK | 1 |
| Meyer, FP | 1 |
| Gamble, G; Hart, H; MacMahon, S; Scott, J; Sharpe, N; Simes, J; White, H | 1 |
| Wehmeier, T; Ziajka, PE | 1 |
| Aberg, G; Beyer, S; Durham, S; Goller, N; Kowala, MC; Recce, R; Valentine, M | 1 |
| Dai, E; Liu, LY; Lucas, A; Nation, PN | 1 |
| Maranhão, RC; Santos, RD | 1 |
| Braunwald, E; Flaker, GC; Goldman, S; Moye, LA; Pfeffer, MA; Ridker, PM; Rifai, N; Sacks, FM | 1 |
| Eriksson, M | 1 |
| Sinzinger, H | 1 |
| Echeandia, C; Figuerola, A; Marta-Moreno, J; Mola, S; Oliveros-Cid, A | 1 |
| Aggeli, KI; Barbetseas, JD; Frogoudaki, AA; Lambrou, SG; Pitsavos, CE; Skoumas, IN; Stefanadis, CI; Toutouzas, PK | 1 |
| Henry, RY; Kendall, MJ | 1 |
| Horikoshi, H; Ito, T; Shiomi, M; Tsujita, Y; Tsukada, T | 1 |
| López Miranda, J; Pérez Jiménez, F; Zambrana García, JL | 1 |
| Azuma, N; Matsugane, T; Motohashi, K; Nishide, T; Nobuto, T; Suzuki, M; Yamane, S | 1 |
| Komukai, M; Morisaki, N; Saito, Y; Shinomiya, M; Tashiro, J; Wajima, YS | 1 |
| Bartek, J; Růzicka, V; Stejskal, D | 1 |
| Constans, J | 1 |
| Bandoh, T; Hayashi, S; Ishikawa, J; Kimura, M; Kusumi, Y; Mitani, H; Niihashi, M; Sakurai, I; Totsuka, T | 1 |
| Stalenhoef, AF; Stehouwer, CD | 1 |
| Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
| Caldwell, RW; Kaesemeyer, WH | 1 |
| Browner, WS; Grady, D; Hulley, SB | 1 |
| Fuyuki, T; Horiguchi, F; Makita, K; Masuda, A; Nozawa, S; Ohta, H; Suda, Y; Sugimoto, I; Takamatsu, K | 1 |
| Applegate, WB; Crouse, JR; Davis, KB; Egan, D; Elam, MB; Garg, R; Herd, JA; Hunninghake, DB; Johnson, WC; Kennedy, JW; Kostis, JB; Sheps, DS | 1 |
| Ose, L; Risberg, K; Svilaas, A; Thoresen, M | 1 |
| Aikawa, M; Enomoto, M; Fukumoto, Y; Hill, CC; Hirouchi, Y; Libby, P; Rabkin, E; Shiomi, M | 1 |
| Dzien, A; Dzien-Bischinger, C; Hoppichler, F; Lechleitner, M | 1 |
| Bachmann, GA; Callister, TQ; Davidson, M; Kafonek, S; Laskey, R; Pittman, D; Raggi, P; Scott, R; Welty, FK | 1 |
| Ouchi, Y | 1 |
| Iizuka, A; Itakura, H; Komatsu, Y; Kondo, K; Kubo, M; Matsumiya, T; Matsumoto, A; Takeda, H; Yoshie, F | 1 |
| Enomoto, M; Hirouchi, Y; Ito, T; Shiomi, M | 2 |
| Egashira, K; Inoue, S; Kataoka, C; Kitamoto, S; Koyanagi, M; Ni, W; Takeshita, A | 1 |
| Faust, M; Kotzka, J; Krone, W; Müller-Wieland, D | 1 |
| Alfón, J; Badimon, L; Berrozpe, M; Martínez-González, J | 1 |
| Freedman, DS; Otvos, JD; Rosenson, RS; Shalaurova, I | 1 |
| Ishikawa, T; Ito, H; Nakamura, H; Ohashi, Y; Orimo, H; Ouchi, Y; Saito, Y | 1 |
| Steiner, G | 1 |
| Barbaki, P; Dagre, AG; Lekakis, JP; Papaioannou, TG; Papamichael, CM; Stamatelopoulos, KS; Stamatelopoulos, SF | 1 |
| Bru, C; Campistol, JM; Cofan, F; Cofan, M; Gilabert, R; Nunez, I; Oppenheimer, F; Ros, E; Zambon, D | 1 |
| Campistol, JM; Casals, E; Cofan, F; Cofan, M; Laguna, JC; Oppenheimer, F; Ros, E; Zambon, D | 1 |
| Aoyagi, S; Fujii, T; Hiromoto, M; Itoh, S; Matsuzaki, M; Tanaka, M; Toma, Y; Tomochika, Y; Umemoto, S | 1 |
| Itakura, H | 1 |
| Ishibashi, T; Maruyama, Y; Nagata, K; Ohkawara, H; Sakamoto, T; Sakurada, S; Shindo, J; Sugimoto, K; Takuwa, Y; Teramoto, T; Yokoyama, K | 1 |
| Bond, MG; Byington, RP; Crouse, JR; Espeland, MA; Furberg, CD; McGovern, M; Sprinkle, JW | 1 |
| Toyota, T | 1 |
| Iwado, S; Kishida, Y; Naito, A; Terahara, A; Tsujita, Y | 1 |
| alHinai, A; Amorosa, LF; Ananthakrishnan, R; Armenian, B; Coly, E; Khachadurian, AK; Martucci, C; Rozovski, SJ; Schneider, SH; Shimamura, T | 1 |
| Mimura, K; Yukawa, S | 1 |
| Arai, M; Fukami, M; Fukushige, J; Ito, T; Kuroda, M; Shiomi, M; Tamura, A; Tsujita, Y; Watanabe, Y | 1 |
| Arai, H; Ishii, K; Kawai, C; Kita, T; Kume, N; Nagano, Y; Otani, H; Ueda, Y; Yokode, M | 1 |
21 review(s) available for pravastatin and Arteriosclerosis
| Article | Year |
|---|---|
Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice.
Topics: Age Factors; Anticholesteremic Agents; Arteriosclerosis; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Humans; Inflammation; Pravastatin; Risk Factors; Sensitivity and Specificity | 2002 |
[Pravastatin: pharmacological action, pleiotropic effects and efficacy in prevention of atherosclerosis].
Topics: Anticholesteremic Agents; Arteriosclerosis; Hepatocytes; Humans; Pravastatin | 2002 |
Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.
Topics: Age Factors; Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Randomized Controlled Trials as Topic; Sex Factors; Survival Analysis; Treatment Outcome | 1995 |
[HMG-CoA reductase inhibitor, pravastatin].
Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Organ Specificity; Pravastatin; Species Specificity | 1993 |
[The pharmacology of the statins: the evidence of a direct antiatherosclerotic action].
Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Lovastatin; Pravastatin; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Statins do more than just lower cholesterol.
Topics: Anticholesteremic Agents; Arteries; Arteriosclerosis; Blood; Cholesterol; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Simvastatin | 1996 |
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Topics: Anticholesteremic Agents; Arteriosclerosis; Brain; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Food-Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver; Lovastatin; Pravastatin; Simvastatin | 1997 |
The hypertensive patient with multiple risk factors: is treatment really so difficult?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Clinical Trials as Topic; Coronary Disease; Female; Fosinopril; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pravastatin; Risk Factors | 1997 |
[Endothelium, lipids and atherosclerosis].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Endocytosis; Endothelium, Vascular; Foam Cells; Humans; Hypercholesterolemia; Lipoproteins, LDL; Pravastatin; Probucol; Rabbits; Vitamin E | 1997 |
Peripheral neuropathy and lipid-lowering therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Statins have other beneficial properties besides their cholesterol lowering effect].
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Coagulation; Clinical Trials as Topic; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Lovastatin; Pravastatin; Simvastatin | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
[Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
Topics: Adult; Arteriosclerosis; Cerebrovascular Disorders; Cholesterol; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
Does cholesterol lowering prevent stroke?
Topics: Anticholesteremic Agents; Arteriosclerosis; Cerebrovascular Disorders; Diagnostic Imaging; Humans; Hypercholesterolemia; Meta-Analysis as Topic; Multicenter Studies as Topic; Pravastatin; Risk Factors | 1998 |
[Hyperlipidemia following heart transplantation. Pathogenic mechanisms and treatment].
Topics: Arteriosclerosis; Cholesterol, VLDL; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Postoperative Complications; Pravastatin; Preoperative Care | 1999 |
[Additional effects of statins independent of the cholesterol-lowering as yet not shown to be clinically relevant].
Topics: Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 2000 |
Non-lipid-related effects of statins.
Topics: Animals; Arteriosclerosis; Blood Coagulation; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Esterification; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Simvastatin | 2000 |
[PATE Study [Pravastatin anti-Atherosclerosis Trial in the Elderly Study]].
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Female; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Pravastatin; Prospective Studies; Risk | 2001 |
[Cholesterin synthase inhibition and atherosclerosis].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; CCAAT-Enhancer-Binding Proteins; Cholesterol; Cholesterol, LDL; Coenzyme A Ligases; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA Synthase; Hyperlipidemias; Pravastatin; Pyridines; Randomized Controlled Trials as Topic; Sterol Regulatory Element Binding Protein 1; Transcription Factors | 2001 |
The use of fibrates and of statins in preventing atherosclerosis in diabetes.
Topics: Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Clofibrate; Diabetes Complications; Diabetes Mellitus; Humans; Hypolipidemic Agents; Pravastatin; Simvastatin | 2001 |
[Research and development of pravastatin].
Topics: Animals; Arteriosclerosis; Chemical Phenomena; Chemistry, Physical; Drug Stability; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver; Molecular Structure; Penicillium; Pravastatin; Streptomyces | 1991 |
36 trial(s) available for pravastatin and Arteriosclerosis
| Article | Year |
|---|---|
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Topics: Adult; Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Tunica Intima; Ultrasonography | 2002 |
Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin.
Topics: Arginine; Arteriosclerosis; Cholesterol, LDL; Diabetes Mellitus, Type 1; Female; Humans; Hypercholesterolemia; Incidence; Male; Pravastatin; Predictive Value of Tests; Probability; Reference Values; Risk Assessment; Sensitivity and Specificity | 2003 |
Marked low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrroles; Tunica Intima; Ultrasonography | 2004 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Biomarkers; C-Reactive Protein; Chemokine CCL2; Cholesterol; Comorbidity; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Male; Middle Aged; Olmesartan Medoxomil; Pravastatin; Prospective Studies; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome; Tumor Necrosis Factor-alpha; Vasculitis | 2004 |
Long-term effects of statins on arterial pressure and stiffness of hypertensives.
Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Cholesterol; Elasticity; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prospective Studies; Pulsatile Flow; Simvastatin; Single-Blind Method | 2005 |
Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia.
Topics: Arteriosclerosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Male; Middle Aged; Pravastatin; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Simvastatin; Tumor Necrosis Factor Decoy Receptors | 2004 |
Effects of combined estriol/pravastatin therapy on intima-media thickness of common carotid artery in hyperlipidemic postmenopausal women.
Topics: Arteriosclerosis; Carotid Artery, Common; Disease Progression; Drug Therapy, Combination; Estriol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Postmenopause; Pravastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging.
Topics: Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pilot Projects; Pravastatin; Pyrroles; Reproducibility of Results; Simvastatin | 2004 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Aspirin; Drug Therapy, Combination; Female; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Patient Dropouts; Patient Selection; Pilot Projects; Pravastatin; Ramipril; Treatment Refusal; Vitamin B Complex | 2005 |
The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression.
Topics: Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Carotid Artery Diseases; Double-Blind Method; Enzyme Inhibitors; Femoral Artery; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipids; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Oxidation-Reduction; Pravastatin; Ultrasonography; Vitamin E | 1995 |
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II).
Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Death, Sudden, Cardiac; Double-Blind Method; Female; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Tunica Intima; Ultrasonography | 1995 |
Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Carotid Artery Diseases; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin | 1995 |
Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.
Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, LDL; Cohort Studies; Double-Blind Method; Femoral Artery; Finland; Humans; Hypercholesterolemia; Intracranial Arteriosclerosis; Lipids; Male; Middle Aged; Pravastatin; Risk Factors; Smoking; Time Factors; Ultrasonography; Vitamin E | 1995 |
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)
Topics: Arteriosclerosis; Carotid Arteries; Cholesterol; Double-Blind Method; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Pravastatin; Ultrasonography | 1995 |
Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects.
Topics: Aged; Arteriosclerosis; Carotid Artery Diseases; Clinical Protocols; Double-Blind Method; Female; Fosinopril; Humans; Hypercholesterolemia; Hypertension; Italy; Male; Middle Aged; Pravastatin; Ultrasonography | 1993 |
Comparison of the lens opacities classification system II and Lensmeter 701.
Topics: Adult; Arteriosclerosis; Cataract; Cholesterol, LDL; Humans; Hypercholesterolemia; Lens Cortex, Crystalline; Lens Nucleus, Crystalline; Male; Middle Aged; Ophthalmology; Photography; Pravastatin; Sensitivity and Specificity | 1993 |
Lens opacity increase in a longitudinal study: comparison of the lens opacities classification system II and lensmeter 701.
Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Cataract; Evaluation Studies as Topic; Humans; Hypercholesterolemia; Lens, Crystalline; Longitudinal Studies; Male; Middle Aged; Ophthalmology; Pravastatin; Prospective Studies; Sensitivity and Specificity | 1996 |
Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dL: baseline results from the Cholesterol and Recurrent Events (CARE) Study.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Coronary Disease; Cross-Sectional Studies; Female; Humans; Intracranial Arteriosclerosis; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peripheral Vascular Diseases; Pravastatin; Prevalence; Recurrence; Risk Factors; Smoking | 1996 |
Association between low plasma vitamin E concentration and progression of early cortical lens opacities.
Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Cataract; Chromatography, High Pressure Liquid; Disease Progression; Finland; Humans; Linear Models; Male; Middle Aged; Pravastatin; Risk Factors; Time Factors; Vitamin E | 1996 |
Increased oxidation resistance of atherogenic plasma lipoproteins at high vitamin E levels in non-vitamin E supplemented men.
Topics: Adult; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Ascorbic Acid; beta Carotene; Cholesterol, LDL; Copper; Dietary Fats; Double-Blind Method; Humans; Hypercholesterolemia; Linoleic Acid; Linoleic Acids; Lipids; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Risk Factors; Smoking; Vitamin E | 1996 |
The hypertensive patient with multiple risk factors: is treatment really so difficult?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Clinical Trials as Topic; Coronary Disease; Female; Fosinopril; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pravastatin; Risk Factors | 1997 |
Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group.
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Arteriosclerosis; Carotid Artery, Common; Carotid Stenosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; New Zealand; Pravastatin; Risk Factors; Treatment Outcome; Triglycerides; Ultrasonography | 1998 |
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
Topics: Aged; Apolipoproteins; Arteriosclerosis; C-Reactive Protein; Cholesterol; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocarditis; Pravastatin; Protein Precursors; Recurrence; Risk Factors; Serum Amyloid A Protein | 1998 |
[Serum leptin, early atherosclerosis and hypolipidemia (a new, previously undescribed effect of pravastatin, a hypolipemic agent)].
Topics: Adipose Tissue; Age of Onset; Arteriosclerosis; Body Mass Index; Female; Fenofibrate; Humans; Hypolipidemic Agents; Insulin; Leptin; Male; Middle Aged; Pravastatin; Proteins; Simvastatin | 1998 |
Usefulness of HMG-CoA reductase inhibitor in Japanese hyperlipidemic women within seven years of menopause.
Topics: Arteriosclerosis; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Japan; Lipids; Menopause; Middle Aged; Pravastatin | 2000 |
Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease.
Topics: Aged; Anticholesteremic Agents; Anticoagulants; Antioxidants; Arteriosclerosis; Aspirin; Cholesterol, LDL; Feasibility Studies; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Niacin; Platelet Aggregation Inhibitors; Pravastatin; Risk Factors; Self Medication; Time Factors; Treatment Outcome; Triglycerides; Vitamins; Warfarin | 2000 |
Statin therapy and plasma C-reactive protein levels in primary prevention.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Biomarkers; C-Reactive Protein; Cholesterol; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin | 2000 |
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Postmenopause; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Reproducibility of Results; Safety; Tomography, X-Ray Computed | 2001 |
Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial.
Topics: Aged; Arteriosclerosis; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin | 2002 |
A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Arteriosclerosis; Cardiovascular Diseases; Cholesterol; Diabetes Complications; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Risk Factors; Safety; Triglycerides | 2001 |
Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients.
Topics: Arteriosclerosis; Carotid Arteries; Carotid Stenosis; Disease Progression; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Transplantation; Lipids; Male; Postoperative Complications; Pravastatin; Time Factors | 2002 |
Pravastatin improves low-density lipoprotein oxidation in renal transplantation.
Topics: Adult; Aged; Arteriosclerosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Lipids; Lipoproteins, LDL; Liver Function Tests; Male; Middle Aged; Oxidation-Reduction; Patient Selection; Postoperative Complications; Pravastatin | 2002 |
[Results of clinical epidemiology and intervention trial of hyperlipidemia in Japan].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Japan; Male; Middle Aged; Pravastatin; Prospective Studies; Simvastatin; Treatment Outcome | 2002 |
Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome.
Topics: Aged; Arteriosclerosis; Carotid Arteries; Carotid Artery Diseases; Double-Blind Method; Female; Humans; Lipids; Male; Middle Aged; Pravastatin; Research Design; Ultrasonography | 1992 |
57 other study(ies) available for pravastatin and Arteriosclerosis
| Article | Year |
|---|---|
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Molecular Structure; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2001 |
Effect of folic acid combined with pravastatin on arteriosclerosis in elderly hypertensive patients with lacunar infarction.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Blood Pressure; Carotid Intima-Media Thickness; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Folic Acid; Humans; Hypertension; Lipids; Male; Middle Aged; Pravastatin; Stroke, Lacunar | 2021 |
Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Drug Administration Schedule; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Macaca fascicularis; Male; Matrix Metalloproteinases; Pravastatin; Simvastatin; Thromboplastin; Tunica Intima; Tunica Media; Vascular Cell Adhesion Molecule-1; Vasodilation | 2002 |
Low-density lipoprotein lowering and atherosclerosis progression: does more mean less?
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Pravastatin; Pyrroles; Ultrasonography | 2002 |
Zeroing in on how low cholesterol should go.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Risk Factors | 2002 |
Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Topics: Animals; Antioxidants; Arteriosclerosis; Coenzymes; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipoproteins, LDL; Liver; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Probucol; Pyridines; Rats; Time Factors; Ubiquinone; Vitamin E | 2003 |
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Blotting, Western; CD40 Antigens; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblasts; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interferon-gamma; Lovastatin; Macrophages; Mevalonic Acid; Mice; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Simvastatin; Transcription Factors | 2003 |
Pravastatin decreases cold ischemia--but not alloantigen-dependent transplant arteriosclerosis.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Cold Temperature; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Isoantigens; Male; Pravastatin; Rats; Rats, Inbred BN; Rats, Inbred Lew; Transplantation, Homologous; Transplantation, Isogeneic; Tunica Intima | 2003 |
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?
Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Is Lipitor better than Pravachol?
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles | 2004 |
What to do about cholesterol now. Here's the take-home message from startling new research findings.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Biomedical Research; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles | 2004 |
Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aorta, Abdominal; Aortic Diseases; Arteriosclerosis; Catheterization; Chemokine CCL2; Chemotaxis; Cholesterol; Cytokines; Diet, Atherogenic; DNA, Complementary; Drug Evaluation, Preclinical; Genetic Therapy; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iliac Artery; Immunoglobulin G; Immunoglobulin M; Inflammation; Macaca fascicularis; Male; Peptidyl-Dipeptidase A; Phenotype; Pravastatin; Random Allocation; Renin; Transfection | 2004 |
Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukins; Male; Matrix Metalloproteinases; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Tissue Inhibitor of Metalloproteinases; Tumor Necrosis Factor-alpha; Ultrasonography | 2004 |
Therapy and clinical trials: clinical therapy and trials.
Topics: Arteriosclerosis; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Pravastatin; Risk Factors | 2004 |
Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Brachiocephalic Trunk; Cholesterol, Dietary; Diet, Atherogenic; Dietary Fats; Drug Evaluation, Preclinical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pravastatin; Rupture, Spontaneous | 2005 |
Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses.
Topics: Arteriosclerosis; Cells, Cultured; Chemokine CCL2; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Interleukin-6; Interleukin-8; Mevalonic Acid; NF-kappa B; Pravastatin; Radiotherapy; Thrombosis | 2005 |
[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2005 |
Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cholesterol; Coronary Vessels; Hyperlipidemias; Hyperplasia; Macrophages; Muscle, Smooth, Vascular; Pravastatin; Rabbits | 1995 |
Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cell Division; Cell Movement; Cells, Cultured; Cholesterol Esters; Diterpenes; Farnesol; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Macrophages, Peritoneal; Male; Mevalonic Acid; Mice; Mice, Inbred BALB C; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Rats; Rats, Sprague-Dawley; Simvastatin | 1995 |
Regression of transplant coronary artery disease during chronic HELP therapy: a case study.
Topics: Arteriosclerosis; Chemical Precipitation; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Extracorporeal Circulation; Fibrinogen; Follow-Up Studies; Heart Transplantation; Humans; Hypercholesterolemia; Lipoprotein(a); Male; Middle Aged; Pravastatin; Time Factors | 1995 |
[Interventions in Atherosclerosis, Issues and Benefits. Proceedings of a symposium of the 62nd Congress of the European Atherosclerosis Association. Jerusalem, 5-9 September 1993].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Humans; Pravastatin | 1993 |
The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Bradykinin; Cholesterol; Coronary Circulation; Endothelium, Vascular; Female; In Vitro Techniques; Lipids; Male; Methacholine Chloride; Pravastatin; Rabbits; Sodium Nitrite; Vasodilation | 1993 |
Primary prevention of stroke.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Arteriosclerosis; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hypercholesterolemia; Lovastatin; Meta-Analysis as Topic; Oxidoreductases; Pravastatin; Simvastatin | 1996 |
Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Echocardiography, Transesophageal; Elasticity; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin; Probucol; Reproducibility of Results | 1996 |
Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.
Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Artery Diseases; Chemoprevention; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Support Techniques; Hospitalization; Humans; Life Expectancy; Life Tables; Male; Markov Chains; Middle Aged; Myocardial Infarction; Placebos; Pravastatin; Risk Factors; Treatment Outcome; Value of Life | 1996 |
Improved survival with statin therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Coronary Disease; Humans; Lovastatin; Pravastatin; Simvastatin | 1996 |
Effects of low-dose pravastatin sodium on plasma cholesterol levels and aortic atherosclerosis of heterozygous WHHL rabbits fed a low cholesterol (0.03%) enriched diet for one year.
Topics: Animals; Aortic Diseases; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Coronary Disease; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Heterozygote; Hyperlipidemias; Male; Pravastatin; Rabbits; Time Factors | 1997 |
HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
Topics: Animals; Arteriosclerosis; Cell Division; Cholesterol; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Macrophages; Male; Mevalonic Acid; Mice; Mice, Inbred C3H; Oxidation-Reduction; Pravastatin; Simvastatin | 1997 |
[Management of atherosclerosis--new findings for the practice].
Topics: Anticholesteremic Agents; Arteriosclerosis; Coronary Vessels; Humans; Pravastatin | 1995 |
Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys.
Topics: Acetylcholine; Animals; Anticholesteremic Agents; Arteriosclerosis; Confounding Factors, Epidemiologic; Coronary Artery Disease; Coronary Vessels; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Macaca fascicularis; Pravastatin; Time Factors; Vasoconstriction; Vasodilation | 1998 |
No primary prevention by pravastatin.
Topics: Anticholesteremic Agents; Arteriosclerosis; Coronary Disease; Humans; Pravastatin | 1998 |
Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Arteriosclerosis; Blood Pressure; Captopril; Cholesterol; Cricetinae; Immunohistochemistry; Lipids; Lipoproteins; Male; Mesocricetus; Peptidyl-Dipeptidase A; Pravastatin; RNA, Messenger | 1998 |
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arteriosclerosis; Carotid Arteries; Chickens; Cholesterol; Disease Models, Animal; Herpesvirus 2, Gallid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Isoquinolines; Lymphocytes; Marek Disease; Pravastatin; Quinapril; Tetrahydroisoquinolines | 1998 |
[Comparison of hypercholesterolemic men and women at high risk for atherosclerosis. Study of risk factors and response to pravastatin treatment].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Blood Pressure; Body Weight; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Patient Selection; Pravastatin; Risk Factors; Sex Factors | 1998 |
Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Aorta, Thoracic; Arteriosclerosis; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin; Treatment Outcome; Ultrasonography | 1998 |
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Chromans; Coronary Vessels; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Glucose Tolerance Test; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperinsulinism; Hyperlipoproteinemia Type II; Hypoglycemic Agents; Insulin Resistance; Male; Pravastatin; Rabbits; Thiazoles; Thiazolidinediones; Troglitazone; Xanthomatosis | 1999 |
Double filtration plasmapheresis maintains normal adhesion molecule levels.
Topics: Anticholesteremic Agents; Arteriosclerosis; Biomarkers; Cell Adhesion Molecules; Cholesterol; Disease Progression; Endothelium, Vascular; Filtration; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intercellular Adhesion Molecule-1; Myocardial Ischemia; Peripheral Vascular Diseases; Plasmapheresis; Pravastatin; Thrombomodulin; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 1998 |
Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration.
Topics: Animals; Anticoagulants; Arteriosclerosis; Becaplermin; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; Cell Division; Cell Movement; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mevalonic Acid; Muscle, Smooth, Vascular; Naphthalenes; Platelet-Derived Growth Factor; Pravastatin; Proto-Oncogene Proteins c-sis; Pyrans; Rabbits; Receptors, LDL; Tumor Cells, Cultured; Tunica Intima | 1999 |
[Atherosclerosis. Congress of the European Atherosclerosis Society (EAS), Athens (Greece), 26-29 May 1999].
Topics: Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Ascorbic Acid; Cholesterol, LDL; Diet; Europe; Folic Acid; Greece; Humans; Hyperhomocysteinemia; Lipoproteins; Pravastatin; Pyridoxine; Risk Factors; Societies, Medical; Triglycerides | 1999 |
Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cholesterol, Dietary; Disease Progression; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Hemolytic Plaque Technique; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Peroxidation; Lipid Peroxides; Lipids; Macrophages; Male; Muscle, Smooth, Vascular; Pravastatin; Rabbits; Thiobarbituric Acid Reactive Substances | 2000 |
Atherosclerosis and nitric oxide production.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Biomarkers; C-Reactive Protein; Lipids; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pravastatin; Rabbits | 2000 |
Statins: underused by those who would benefit.
Topics: Age Factors; Arteriosclerosis; Clinical Trials as Topic; Coronary Disease; Humans; Hypolipidemic Agents; Legislation, Drug; Lovastatin; Nonprescription Drugs; Pravastatin; Self Medication; United States | 2000 |
Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Male; Middle Aged; Norway; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Simvastatin; Surveys and Questionnaires | 2000 |
Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Arteriosclerosis; Azo Compounds; Cell Division; Cells, Cultured; Collagen; Coloring Agents; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunohistochemistry; Indoles; Lipids; Macrophages; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Muscle, Smooth; Pravastatin; Procollagen; Rabbits; RNA, Messenger | 2001 |
Protective effects of Saiko-ka-ryukotsu-borei-to (Chai-Hu-Jia-Long-Gu-Mu-Li-Tang) against atherosclerosis in Kurosawa and Kusanagi-hypercholesterolemic (KHC) rabbits.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Arteriosclerosis; Chromatography, High Pressure Liquid; Drugs, Chinese Herbal; Female; Gene Expression; Hypercholesterolemia; Lipids; Liver; Pravastatin; Rabbits; Receptors, LDL; RNA, Messenger; Spectrophotometry, Ultraviolet | 2001 |
Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Muscle, Smooth, Vascular; Pravastatin; Rabbits | 2001 |
Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Blood Pressure; Chemokine CCL2; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Lipids; Macrophages; Male; Monocytes; NG-Nitroarginine Methyl Ester; Nitrates; Nitric Oxide Synthase; Nitrites; Nitroarginine; Peptidyl-Dipeptidase A; Pravastatin; Proliferating Cell Nuclear Antigen; Pyridines; Rats; Rats, Inbred WKY; rhoA GTP-Binding Protein; RNA, Messenger; Systole; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2001 |
HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
Topics: Animals; Aorta; Arteries; Arteriosclerosis; Atorvastatin; Carotid Arteries; Chemokine CCL2; Cholesterol; Coronary Vessels; Down-Regulation; Femoral Artery; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iliac Artery; Immunohistochemistry; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pravastatin; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine | 2001 |
Stability of atheromatous plaque affected by lesional composition: study of WHHL rabbits treated with statins.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Disease Models, Animal; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Lipids; Pravastatin; Rabbits | 2001 |
Comparison of low-density lipoprotein cholesterol lowering by pravastatin to <100 mg/dl versus >100 mg/dl on brachial artery vasoreactivity in patients with severe hypercholesterolemia and previous atherosclerotic events or diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Brachial Artery; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus; Drug Administration Schedule; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Treatment Outcome; Vasodilation | 2002 |
Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis.
Topics: Actins; Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Arteriosclerosis; Cholesterol; Diet, Atherogenic; Disease Models, Animal; Elasticity; Hypercholesterolemia; Male; Membrane Transport Proteins; Muscle, Smooth, Vascular; Myosin Heavy Chains; NADH, NADPH Oxidoreductases; NADPH Dehydrogenase; NADPH Oxidases; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphoproteins; Pravastatin; Probucol; Protein Isoforms; Rabbits; Smooth Muscle Myosins; Superoxides | 2002 |
Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; ADP Ribose Transferases; Amides; Arteriosclerosis; Base Sequence; Botulinum Toxins; Cells, Cultured; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Signaling Peptides and Proteins; Monocytes; Plasminogen Activator Inhibitor 1; Polyisoprenyl Phosphates; Pravastatin; Protein Prenylation; Protein Serine-Threonine Kinases; Pyridines; rho GTP-Binding Proteins; rho-Associated Kinases; RNA, Messenger; Signal Transduction | 2002 |
[Diabetes mellitus and hyperlipidemia].
Topics: Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Humans; Hyperlipidemias; Lipid Metabolism; Lovastatin; Pravastatin | 1992 |
Pravastatin decreases serum lipids and vascular cholesterol deposition in Watanabe heritable hyperlipidemic (WHHL) rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Cholesterol; Coronary Vessels; Hydroxyproline; Hyperlipidemias; Lipids; Pravastatin; Rabbits; Receptors, LDL; Triglycerides | 1991 |
[Hyperlipidemia and drug treatment].
Topics: Arteriosclerosis; Carnitine; Cholestyramine Resin; Glomerulonephritis; Humans; Hyperlipidemias; Kidney Failure, Chronic; Niceritrol; Pantetheine; Pravastatin; Probucol; Vitamin E | 1991 |
Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Coronary Disease; Heptanoic Acids; Naphthalenes; Phospholipids; Pravastatin; Rabbits; Triglycerides; Xanthomatosis | 1990 |
Lipoproteins and atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol Esters; Cholestyramine Resin; Disease Models, Animal; Foam Cells; Heptanoic Acids; Hyperlipidemia, Familial Combined; Lipoproteins, LDL; Liver; Macrophages; Mice; Naphthalenes; Pravastatin; Probucol; Rabbits; Receptors, Cell Surface; Receptors, Lipoprotein | 1990 |